Roundhill Russell 2000 0DTE Covered Call Strat ETF vs Zoetis Inc — how do they compare? Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $28.52, while Zoetis Inc trades at $74.43 (market cap $31.59B). The key difference: Zoetis Inc pays a 2.81% dividend while Roundhill Russell 2000 0DTE Covered Call Strat ETF pays none, and Roundhill Russell 2000 0DTE Covered Call Strat ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| RDTE | ZTS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $34.72 | $156.76 |
52-Week Low | $26.40 | $71.91 |
Market Cap | — | $31.59B |
Enterprise Value | — | $38.89B |
Dividend Yield | — | 2.81% |
Signals from Pluang's Aura AI — not financial advice
RDTE stock trades at $28.57, down 0.38% on the day, with a bearish technical signal from moving averages and neutral oscillators. The company has announced multiple small dividends for 2026, but key valuation and profitability ratios are unavailable. Recent news highlights concerns about the fund's strategy and capital erosion risks.
The outlook is cautious due to structural risks in the covered call strategy capping upside and exposing downside, as noted by Seeking Alpha. Investment opportunity hinges on income from dividends, but risks of NAV deterioration and negative media sentiment present significant headwinds for shareholders.
No Aura AI signal available yet.
Trailing returns across standard periods
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →